BR9205771A - Vetor de vírus recombinantes e processo para a fabricaçao do mesmo - Google Patents

Vetor de vírus recombinantes e processo para a fabricaçao do mesmo

Info

Publication number
BR9205771A
BR9205771A BR9205771A BR9205771A BR9205771A BR 9205771 A BR9205771 A BR 9205771A BR 9205771 A BR9205771 A BR 9205771A BR 9205771 A BR9205771 A BR 9205771A BR 9205771 A BR9205771 A BR 9205771A
Authority
BR
Brazil
Prior art keywords
virus vector
pct
nucleotide sequences
recombinant virus
pair
Prior art date
Application number
BR9205771A
Other languages
English (en)
Inventor
Michael Edward Griffith Boursnell
Stephen Charles Inglis
Alan James Munro
Original Assignee
Cantab Pharma Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharma Res filed Critical Cantab Pharma Res
Publication of BR9205771A publication Critical patent/BR9205771A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9205771A 1991-03-14 1992-03-10 Vetor de vírus recombinantes e processo para a fabricaçao do mesmo BR9205771A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919105383A GB9105383D0 (en) 1991-03-14 1991-03-14 An immunotherapeutic for cervical cancer
PCT/GB1992/000424 WO1992016636A1 (en) 1991-03-14 1992-03-10 Recombinant virus vectors encoding human papillomavirus proteins

Publications (1)

Publication Number Publication Date
BR9205771A true BR9205771A (pt) 1994-06-07

Family

ID=10691550

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9205771A BR9205771A (pt) 1991-03-14 1992-03-10 Vetor de vírus recombinantes e processo para a fabricaçao do mesmo

Country Status (18)

Country Link
US (1) US5719054A (pt)
EP (1) EP0576471B1 (pt)
JP (1) JPH06505626A (pt)
KR (1) KR100240183B1 (pt)
CN (1) CN1090239C (pt)
AT (1) ATE208824T1 (pt)
AU (1) AU665531B2 (pt)
BR (1) BR9205771A (pt)
CA (1) CA2106069A1 (pt)
DE (1) DE69232201T2 (pt)
DK (1) DK0576471T3 (pt)
ES (1) ES2168258T3 (pt)
GB (1) GB9105383D0 (pt)
HK (1) HK1001657A1 (pt)
MX (1) MX9205131A (pt)
NO (1) NO310033B1 (pt)
OA (1) OA10085A (pt)
WO (1) WO1992016636A1 (pt)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
AT399656B (de) * 1993-03-19 1995-06-26 Boehringer Ingelheim Int Verfahren zur herstellung von krebsvakzinen
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8956621B2 (en) * 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
EP0812358A1 (en) * 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
CZ28899A3 (cs) * 1996-07-29 1999-07-14 Cantab Pharmaceuticals Research Limited Polypeptidy použitelné jako imunoterapeutická činidla a způsoby přípravy polypeptidů
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
WO1998013500A2 (en) * 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1999027964A1 (en) * 1997-12-01 1999-06-10 Cfy Biomedicals, Inc. Multivalent recombinant antibodies for treating hrv infections
PL343064A1 (en) * 1998-03-20 2001-07-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6541002B1 (en) 1998-03-30 2003-04-01 Thomas Jefferson University Compositions and methods for providing a protein to a virion
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
JP2002524078A (ja) * 1998-09-04 2002-08-06 アヴェンティス パスツール リミテット゛ 子宮頸がんの治療
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
WO2001019408A1 (en) 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
AU2007201619B2 (en) * 1999-09-16 2011-05-12 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
ATE525091T1 (de) 2000-03-13 2011-10-15 Engene Inc Zusammensetzungen und verfahren zur regulierten proteinexpression im darm
US20040102388A1 (en) * 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
US20030170642A1 (en) * 2001-03-12 2003-09-11 Irm, Llc Identification of cellular targets for biologically active molecules
WO2002072789A2 (en) * 2001-03-12 2002-09-19 Irm, Llc. Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
EP1425039A4 (en) * 2001-03-23 2005-02-02 Us Gov Health & Human Serv PEPTIDES THAT GIVE AN IMMUNE REACTION WITH THE HUMAN PAPILLOMA VIRUS
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
AU2002365196C1 (en) 2001-07-19 2009-08-13 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
AU2002364124A1 (en) * 2001-11-28 2003-06-10 The Burnham Institute Methods for identifying modulators of apoptosis
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
CN1720060B (zh) 2002-10-03 2011-12-14 惠氏控股公司 人乳头瘤病毒多肽和免疫原性组合物
ATE465753T1 (de) * 2002-10-21 2010-05-15 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
WO2004073641A2 (en) * 2003-02-18 2004-09-02 Kevin Slawin Induced activation in dendritic cells
WO2005014642A2 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
EP1732596A2 (en) * 2004-03-11 2006-12-20 Shantha West, Inc. Therapeutic use of rm1 antigen
JP4881874B2 (ja) 2004-12-06 2012-02-22 協和発酵キリン株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用
NZ561883A (en) 2005-03-23 2010-11-26 Genmab As Antibodies against CD38 for treatment of multiple myeloma
CN1308036C (zh) * 2005-03-28 2007-04-04 浙江大学医学院附属妇产科医院 一种hpv多肽疫苗及其制备方法
AU2006287441B2 (en) * 2005-09-07 2012-09-06 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CA2524619A1 (en) 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AU2007243442A1 (en) * 2006-04-24 2007-11-08 Shantha West, Inc. AgRM2 antigen
KR101141333B1 (ko) * 2006-06-20 2012-05-23 트랜스진 에스.에이. 재조합 바이러스 백신
US8052968B2 (en) * 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
EP2076272B1 (en) 2006-10-19 2015-07-29 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
EP2101813B1 (en) 2006-11-27 2014-04-02 Patrys Limited Novel glycosylated peptide target in neoplastic cells
CA2675355C (en) * 2007-01-30 2015-04-28 Transgene S.A. Papillomavirus vaccine
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2008138648A1 (en) * 2007-05-15 2008-11-20 Transgene S.A. Vectors for multiple gene expression
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
EP2171071B1 (en) * 2007-06-15 2015-08-05 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
WO2009058451A2 (en) 2007-08-02 2009-05-07 California Stem Cell, Inc. Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells
AU2008314485B9 (en) * 2007-10-15 2015-02-26 Jingang Medicine (Australia) Pty Ltd Expression system for modulating an immune response
CA2705869C (en) * 2007-11-19 2012-10-30 Philippe Erbs Poxviral oncolytic vectors
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
ES2633470T3 (es) 2008-09-22 2017-09-21 Baylor College Of Medicine Métodos y composiciones de generación de una respuesta inmune mediante la inducción de CD40 y adaptadores de receptores de reconocimiento de patrones
US8211487B2 (en) * 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
CN102459342B (zh) 2009-04-27 2015-01-07 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗il-3ra抗体
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
CN102482327B (zh) 2009-06-22 2014-10-29 财团法人卫生研究院 脂质化肿瘤相关抗原及其免疫治疗的组成物及方法
AU2010291901C1 (en) 2009-09-14 2016-03-03 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus combination cancer therapy
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
EP2661278B1 (en) 2011-01-04 2019-06-19 SillaJen Biotherapeutics, Inc. Tumor specific complement dependent cytotoxicity (cdc) antibodies generated by administration of oncolytic vaccinia virus, for use in the treatment of cancer
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
MY163674A (en) 2011-07-01 2017-10-13 Ngm Biopharmaceuticals Inc Compositions, uses and method for treatment of metabolic disorders and diseases
US9901635B2 (en) 2011-12-21 2018-02-27 Vaccibody As Vaccines against HPV
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
CN102787134B (zh) * 2012-07-20 2014-11-05 西安交通大学 一种用于同源重组的自转运载体及其构建的经粘膜免疫疫苗
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CN105121472A (zh) 2012-10-30 2015-12-02 埃斯佩兰斯医药公司 抗体/药物缀合物及其使用方法
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
JP6403685B2 (ja) 2012-12-27 2018-10-17 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法
JP2016514091A (ja) 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
JP6541639B2 (ja) 2013-03-14 2019-07-10 ベリカム ファーマシューティカルズ， インコーポレイテッド Ｔ細胞増殖をコントロールするための方法
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
US20160152952A1 (en) 2013-06-25 2016-06-02 Temple University-Of The Commonwealth System Of Higher Education Cortical Bone-Derived Stem Cells
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
WO2015123527A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
JP6868554B2 (ja) 2014-09-02 2021-05-12 ベリカム ファーマシューティカルズ， インコーポレイテッド ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
US20160263155A1 (en) 2015-03-10 2016-09-15 Leiden University Medical Center T cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CA3082794A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methods for treatment of bile acid-related disorders
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
KR20180100659A (ko) 2016-01-08 2018-09-11 백시바디 에이에스 치료적 항암 네오에피토프 백신
US10512683B2 (en) * 2017-03-03 2019-12-24 Papivax Biotech Inc. Combination therapies for human papillomavirus-associated diseases comprising administration of therapeutic vaccine and recombinant virus vector
WO2018208849A1 (en) 2017-05-09 2018-11-15 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
US20200347148A1 (en) 2017-12-08 2020-11-05 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
EP4271482A2 (en) 2020-12-31 2023-11-08 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE69031735T2 (de) * 1989-04-18 1998-03-12 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren

Also Published As

Publication number Publication date
DE69232201D1 (de) 2001-12-20
GB9105383D0 (en) 1991-05-01
NO933260L (no) 1993-10-22
HK1001657A1 (en) 1998-07-03
CN1090239C (zh) 2002-09-04
WO1992016636A1 (en) 1992-10-01
US5719054A (en) 1998-02-17
CN1064892A (zh) 1992-09-30
KR100240183B1 (ko) 2000-01-15
MX9205131A (es) 1994-06-30
AU665531B2 (en) 1996-01-11
AU1414792A (en) 1992-10-21
EP0576471A1 (en) 1994-01-05
OA10085A (en) 1996-12-18
JPH06505626A (ja) 1994-06-30
EP0576471B1 (en) 2001-11-14
NO310033B1 (no) 2001-05-07
NO933260D0 (no) 1993-09-13
ATE208824T1 (de) 2001-11-15
CA2106069A1 (en) 1992-09-15
DE69232201T2 (de) 2002-07-11
DK0576471T3 (da) 2002-03-11
ES2168258T3 (es) 2002-06-16

Similar Documents

Publication Publication Date Title
BR9205771A (pt) Vetor de vírus recombinantes e processo para a fabricaçao do mesmo
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
ES8505719A1 (es) Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas
DE69233158D1 (de) Gentechnologisch hergestellter stamm für impfstoffe
DE69430071D1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
ATE328068T1 (de) Papillomavirus vakzine
ES2002490A6 (es) Un metodo de preparar un virus recombinante
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
RU2003103779A (ru) Экспрессионная система
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
DE59610632D1 (de) Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
IL168374A (en) Vaccines against west nile virus
ATE288483T1 (de) Nicht-verbreitendes lebendes herpesvirusvakzin
NO922728L (no) Vaksine mot coccidiose
DE69929530D1 (de) Attenuierte pferdeherpesvirus
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
NO20032097L (no) Gj¶ravledet vaksine mot IPNV
ATE223492T1 (de) Mutanten des infektiösen rinder rhinotracheitis- virus und impfstoffe
RU2000122617A (ru) Самореплицирующийся рекомбинантный вектор, способ его получения, вакцина для иммунизации против вич с помощью днк, содержащая указанный вектор, способ лечения или профилактики вич и клетка-хозяин, содержащая указанный вектор
RU93056615A (ru) Вектор, способ получения вектора, способ получения лекарственного препарата, способ активизации иммунитета
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
WO2002078621A3 (en) Replication-competent recombinant virus and methods of use thereof

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal